Sceletium: How It Works, Uses, and Potential Side Effects

Sceletium tortuosum, commonly called kanna, is a succulent plant from southern Africa whose mood-altering effects stem from a group of alkaloids that act on the brain in at least two distinct ways: they block the reuptake of serotonin and they inhibit an enzyme called PDE4. That dual mechanism sets it apart from most botanical supplements marketed for stress and low mood. But the science behind kanna is more layered than a simple “natural antidepressant” label suggests, and the way the plant is prepared can dramatically change what it actually delivers to your body.

A Plant With Deep Roots

Kanna has been used for millennia by the indigenous Khoe and San peoples of southern Africa. Historically, they chewed or smoked the fermented plant material to quench thirst, fight fatigue, elevate mood, suppress appetite, and mark social and spiritual occasions.¹ The Khoe and Khoen peoples specifically valued it as both an appetite suppressant and a mood elevator, roles that modern pharmacology is now trying to pin down at the molecular level.² The traditional preparation involved crushing the plant material, letting it ferment in a sealed container for several days, and then drying it. That fermentation step turns out to be pharmacologically meaningful, not just a cultural tradition.

What Is Actually in the Plant

Researchers have identified at least 25 alkaloids in Sceletium tortuosum, grouped into four structural families. The mesembrine class dominates.³ Within that family, two compounds get the most research attention: mesembrine and mesembrenone. Both act as serotonin reuptake inhibitors, which gives a pharmacological basis for why the plant has been used traditionally to lift mood. Mesembrenone also shows reasonably strong PDE4 inhibitory activity, adding a second dimension to the plant’s effects.⁴

But the alkaloid profile is not fixed. It shifts depending on the specific plant, where it grew, and crucially, how it was processed. That variability is one reason why two kanna products on a store shelf can feel very different from each other.

How Sceletium Affects the Brain

The working explanation for kanna’s mood and anxiety effects rests on two pharmacological actions happening simultaneously. The first is serotonin reuptake inhibition, the same basic mechanism behind prescription SSRIs. By slowing the removal of serotonin from the spaces between neurons, the alkaloids allow serotonin signals to persist longer. The second is inhibition of PDE4, an enzyme involved in inflammatory signaling and in regulating certain neurotransmitter pathways. The combination of these two actions in a single botanical is unusual, and researchers have argued it could offer anxiolytic potential by dampening the brain’s threat-detection circuitry.⁵

There is a twist, though. Research on a high-mesembrine extract found that serotonin reuptake inhibition may actually be secondary to a different action: monoamine release. In other words, rather than just blocking the recycling of serotonin, certain kanna preparations actively push serotonin (and possibly other monoamines like dopamine and norepinephrine) out of neurons and into the synapse.⁶ This distinction matters: monoamine releasers tend to have faster, more noticeable effects than reuptake inhibitors, and they also carry different risk profiles when combined with other drugs. It helps explain why chewing raw kanna has sometimes been described as producing a stimulant-like buzz, while standardized low-dose extracts feel more like a gentle calming.

What the Amygdala Study Showed

The most frequently cited piece of human neuroscience on kanna comes from an fMRI study using Zembrin, a standardized extract. Researchers gave a single 25 mg dose to healthy volunteers and then scanned their brains while showing them images designed to trigger a fear response. The extract reduced reactivity in the amygdala, the brain region most closely associated with processing threats, and weakened the connection between the amygdala and the hypothalamus, which coordinates the body’s stress response.⁵ This is a proof-of-concept result in a small group of healthy people, not a clinical trial in patients with anxiety disorders. But it does provide a plausible neural explanation for the calming effects that traditional users have reported for centuries.

Animal research further supports the anxiolytic direction. In an anxiety-depression model using chicks (a standard behavioral test), a Sceletium extract fraction at higher doses reduced distress vocalizations during the anxiety phase.⁷

Cognitive Effects

Beyond mood and anxiety, there is early evidence that kanna extracts can sharpen certain types of thinking. A randomized, placebo-controlled trial in cognitively healthy subjects found that 25 mg of Zembrin daily improved cognitive set flexibility and executive function compared with placebo.⁸ Cognitive flexibility refers to your ability to switch between tasks or mental rules, while executive function covers planning, decision-making, and impulse control. The researchers connected these effects to PDE4 inhibition, since PDE4 is implicated in signaling pathways relevant to memory and learning.

The study was small and designed as a proof of concept, so it is far too early to call kanna a cognitive enhancer with any confidence. But it does suggest that the PDE4 side of the plant’s mechanism may contribute something beyond mood regulation.

The Synergy Question

One interesting finding from recent laboratory work is that mesembrine alone can reproduce much of the anxiolytic effect of a full Zembrin extract, but no single isolated alkaloid could reproduce the antidepressant-like effect. Only the complete extract, at its highest tested concentration, reversed depression-like behavior in the model used.⁹ This suggests the antidepressant activity depends on multiple alkaloids working together, or possibly on non-alkaloid components that haven’t been fully characterized yet. It’s a pattern that shows up across herbal medicine: isolating a single “active ingredient” sometimes fails to capture what the whole plant does.

Why Fermentation Changes Everything

The traditional Khoe and San practice of fermenting kanna before use is not arbitrary. Fermentation dramatically alters the alkaloid profile. In one study, mesembrine content dropped from about 1.33% to just 0.05% over ten days of fermentation, while a different compound (Δ7mesembrenone) appeared in measurable amounts.¹⁰ Another study found the opposite pattern for certain preparations: mesembrine levels actually climbed after fermentation while mesembrenone levels fell, and total alkaloid content increased.¹¹

These seemingly contradictory results likely reflect differences in the specific fermentation methods, starting plant material, and environmental conditions. The practical takeaway is that fermentation is not a neutral step. It reshapes the chemistry in ways that can either enhance or reduce the psychoactive alkaloids. The traditional approach, which the KhoiSan refined over generations, appears tuned to increase the compounds most responsible for the mood-altering effects. Modern manufacturers of standardized extracts bypass traditional fermentation entirely and instead use controlled extraction processes designed to hit a target alkaloid profile.

How Your Body Absorbs It

One reason kanna was traditionally chewed rather than swallowed as a pill has a pharmacological basis. Laboratory tests on porcine tissue (a common stand-in for human mucosa) showed that mesembrine crosses intestinal tissue very efficiently, even better than caffeine, which is considered highly permeable. The other major alkaloids also crossed intestinal tissue well. Absorption through the tissues of the mouth (sublingual and buccal) was lower overall, but still meaningful compared to reference compounds.¹²

The implication is that chewing kanna and holding it in the mouth delivers alkaloids through two routes simultaneously: absorption through the oral mucosa and swallowed material absorbed through the gut. The oral route may also help the alkaloids bypass first-pass metabolism in the liver, potentially increasing their bioavailability compared with simply swallowing a capsule. This is consistent with the traditional observation that chewing kanna produces faster, more noticeable effects than eating it.

Anti-Inflammatory and Neuroprotective Signals

A growing body of preclinical work points to effects that go beyond classical neurotransmitter modulation. In a rat model of chronic unpredictable stress, a Zembrin extract at 12.5 mg/kg reduced both anhedonia-like and anxiety-like behavior. At the molecular level, it decreased PDE4B expression in the cortex and hippocampus and raised plasma levels of interleukin-10, an anti-inflammatory signaling molecule. At a higher dose of 25 mg/kg, the anti-inflammatory effect (raised interleukin-10) persisted, but there were signs of increased oxidative stress in the cortex, hinting that more is not always better.¹³

Separately, mesembrine itself has been shown to have mild anti-inflammatory and cytoprotective properties, including improving the viability of immune cells exposed to inflammatory stimuli in cell culture.¹⁴ These findings are all preclinical, meaning they come from cells in dishes or from rodents, not from human patients. But they suggest the plant’s traditional reputation as a general tonic may involve more than just serotonin.

Potential Side Effects

Kanna’s side effect profile at typical supplement doses (roughly 8 to 25 mg of standardized extract daily) appears mild based on the limited clinical data available. Reported side effects in human studies have generally been minor and include headache, nausea, and occasional gastrointestinal discomfort. The Zembrin extract used in published clinical trials was tolerated without serious adverse events at 25 mg daily.

The more meaningful safety concern is pharmacological rather than side-effect-based. Because kanna alkaloids act on the serotonin system through both reuptake inhibition and monoamine release, combining kanna with prescription SSRIs, SNRIs, MAOIs, or other serotonergic drugs raises the theoretical risk of serotonin syndrome, a potentially dangerous condition caused by excessive serotonin activity. Symptoms range from agitation, sweating, and rapid heart rate to muscle rigidity and seizures in severe cases. No published case reports of serotonin syndrome from kanna appear in the peer-reviewed literature as of mid-2025, but the pharmacological logic for the risk is sound enough that avoiding the combination is a reasonable precaution.

The monoamine-releasing activity identified in high-mesembrine extracts adds another layer of concern.⁶ Monoamine releasers as a class (which includes substances like amphetamines, though kanna’s potency is far lower) can raise heart rate and blood pressure, and they carry a theoretical risk of dependence at high doses over extended periods. Whether kanna at typical supplement doses poses any meaningful cardiovascular risk or dependence risk is simply unknown, because the long-term safety studies have not been done.

The Quality Control Problem

If you walk into a supplement shop or browse kanna products online, you will find capsules, tinctures, powders, fermented plant material, and isolated extracts, all labeled “kanna” but potentially containing very different alkaloid profiles. The research discussed above used Zembrin, a standardized extract with a defined alkaloid content. Most consumer products do not undergo the same level of characterization. The same analytical challenges that led researchers to develop specialized separation techniques for the plant’s many closely related alkaloid compounds apply to quality control in the supplement market.¹⁵

The regulatory landscape adds to the confusion. Sceletium products must navigate different frameworks depending on the country. In the United States, kanna is sold as a dietary supplement, which means it does not require pre-market approval for safety or efficacy. In the European Union, the path for traditional herbal medicinal products can be prohibitive for plants that lack an established tradition of use within EU borders. Researchers have pointed out that regulatory frameworks designed to protect consumers can inadvertently create barriers for botanicals from developing countries, especially those without the corporate backing to fund the registration process.¹⁶ The result is a market where a well-studied, standardized extract coexists with products of unknown composition, and consumers are largely left to sort out the difference on their own.

Dose Ranges and Practical Guidance

Most clinical studies have used 25 mg daily of the Zembrin standardized extract, and this is the dose with the best evidence behind it for both mood and cognitive effects.⁸ Some users of raw or fermented plant material take considerably higher amounts, but there is almost no controlled data on outcomes at those doses. The rat study mentioned earlier found that doubling the extract dose did not simply double the benefit; it introduced oxidative stress markers that were absent at the lower dose.¹³ Translating animal doses to humans is always imprecise, but the pattern at least cautions against the “if some is good, more is better” approach.

If you are considering kanna, a few practical points are worth keeping in mind. Look for products that specify the extract type and alkaloid standardization. Avoid combining it with prescription antidepressants or anti-anxiety medications without medical guidance, given the serotonin overlap. Start at the low end of any suggested dose range to see how you respond. And keep in mind that the most compelling evidence comes from a single standardized extract studied in small trials of healthy people, not from large-scale clinical trials in patients with diagnosed anxiety or depression. The plant has a remarkable ethnobotanical history and a plausible pharmacological story, but the clinical evidence is still catching up.

Kanna in the Context of Indigenous Knowledge

One dimension of the kanna story that often gets lost in the supplement marketing is the question of who owns the knowledge. The Khoe and San peoples developed the preparation methods that modern science is now validating, including the fermentation techniques shown to optimize the alkaloid profile.¹¹ In South Africa, benefit-sharing agreements have been put in place for some commercialized Sceletium products, but the broader tension between indigenous knowledge and the global supplement industry remains unresolved. Companies can patent extraction processes and create branded products without necessarily compensating the communities whose centuries of empirical observation identified the plant’s value in the first place. Some researchers in the field have explicitly flagged the inadequacy of intellectual property protections for traditional botanicals from developing countries.¹⁶ Whether you view kanna as a promising nootropic or a traditional medicine, its story is incomplete without acknowledging that the pharmacological insights being validated today were discovered, empirically, by people who never had access to an fMRI scanner or a mass spectrometer.